Brokers Offer Predictions for Gracell Biotechnologies Inc.’s FY2024 Earnings (NASDAQ:GRCL)

Gracell Biotechnologies Inc. (NASDAQ:GRCL) – Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Gracell Biotechnologies in a research note issued on Wednesday, November 15th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($0.86) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Gracell Biotechnologies’ current full-year earnings is ($1.03) per share.

A number of other research analysts have also recently issued reports on GRCL. HC Wainwright lifted their price objective on Gracell Biotechnologies from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus initiated coverage on Gracell Biotechnologies in a research note on Thursday, October 19th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, Citigroup dropped their price objective on Gracell Biotechnologies from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, August 29th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gracell Biotechnologies has a consensus rating of “Buy” and a consensus price target of $13.67.

Gracell Biotechnologies Price Performance

Shares of NASDAQ:GRCL opened at $4.94 on Monday. The company has a quick ratio of 6.26, a current ratio of 6.44 and a debt-to-equity ratio of 0.04. The stock has a market cap of $359.03 million, a PE ratio of -4.70 and a beta of -1.32. The company’s fifty day moving average is $3.30 and its 200 day moving average is $3.51. Gracell Biotechnologies has a 52 week low of $1.40 and a 52 week high of $6.99.

Institutional Investors Weigh In On Gracell Biotechnologies

A number of large investors have recently modified their holdings of GRCL. Vivo Capital LLC raised its stake in Gracell Biotechnologies by 174.1% in the third quarter. Vivo Capital LLC now owns 10,881,144 shares of the company’s stock worth $31,338,000 after buying an additional 6,911,717 shares in the last quarter. Sphera Funds Management LTD. purchased a new stake in Gracell Biotechnologies in the first quarter worth $4,391,000. Pivotal bioVenture Partners Investment Advisor LLC purchased a new stake in Gracell Biotechnologies in the third quarter worth $3,960,000. Great Point Partners LLC raised its holdings in Gracell Biotechnologies by 60.7% in the first quarter. Great Point Partners LLC now owns 3,153,206 shares of the company’s stock worth $5,865,000 after purchasing an additional 1,190,807 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Gracell Biotechnologies during the second quarter valued at $3,810,000.

Gracell Biotechnologies Company Profile

Gracell Biotechnologies Inc, a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia.